Record CStone Funding Heralds New Era For China Startups
This article was originally published in PharmAsia News
With $150m in hand and a pipeline covering five therapeutic areas, CStone has already broken the record for the largest Series A investment in a Chinese biopharma startup. If that's not impressive enough, add a CEO from big pharma and support from China’s largest CRO.
Register for our free email digests: